Healwell AI Shares Surge on AI-Platform Demonstration Success

Healwell AI shares rose 3.6% to 1.43 Canadian dollars after the company demonstrated its AI platform generating high-quality data for a major pharmaceutical company, Takeda Pharmaceutical. The demonstration showcased the use of AI to generate real-world data for supporting patient access, product advancement, and reimbursement growth. The platform generated data on dose escalation for vedolizumab, which treats Crohn's disease and ulcerative colitis. The real-world data provided evidence of remission improvement outcomes.